Ebola haemorrhagic fever in Zaire, 1976. Bull WHO, 1978; 56:271–293.
2.
Ebola haemorrhagic fever in Sudan, 1976. Report of a WHO/International Study Team. Bull WHO, 1978; 56:247–270.
3.
SureauPH. Firsthand clinical observations of hemorrhagic manifestations in Ebola hemorrhagic fever in Zaire. Rev Infect Dis, 1989; 11(Suppl 4):S790–793.
4.
BwakaMA, BonnetMJ, CalainP, et al. Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: Clinical observations in 103 patients. J Infect Dis, 1999; 179(Suppl 1):S1–S7.
5.
FormentyP, HatzC, Le GuennoB, StollA, RogenmoserP, WidmerA. Human infection due to Ebola virus, subtype Cote d'Ivoire: Clinical and biologic presentation. J Infect Dis, 1999; 179(Suppl 1):S48–S53.
6.
MbonyeA, WamalaJ, WinyiK, TugumizemoV, AcengJ, MakumbiI. Repeated outbreaks of viral hemorrhagic fevers in Uganda. African Health Sci, 2012; 12:579–583.
7.
American College of Surgeons. Statement on the Surgeon and HIV Infection. 2004.
8.
U.S. Centers for Disease Control and Prevention. Evaluating Patients for Possible Ebola Virus Disease: Recommendations for Healthcare Personnel and Health Officials. 2014.
9.
World Health Organization. Ebola: Protective measures for medical staff. 2014.
10.
GehringG, RohrmannK, AtenchongN, et al. The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry. J Antimicrob Chemother, 2014; 69:2123–2131.
11.
KortepeterMG, LawlerJV, HonkoA, et al. Real-time monitoring of cardiovascular function in rhesus macaques infected with Zaire ebolavirus. J Infect Dis, 2011; 204(Suppl 3):S1000–S1010.
